Demystifying Baxter International: Insights From 4 Analyst Reviews
4 analysts have expressed a variety of opinions on Baxter International (NYSE:BAX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 1 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 1 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.75, a high estimate of $30.00, and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.92%.
Understanding Analyst Ratings: A Comprehensive Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Baxter International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Roman | Goldman Sachs | Lowers | Neutral | $17.00 | $21.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $25.00 | $30.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $30.00 | $36.00 |
| Patrick Wood | Morgan Stanley | Lowers | Underweight | $15.00 | $19.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baxter International. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baxter International compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Baxter International's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Baxter International's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Baxter International analyst ratings.
About Baxter International
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Key Indicators: Baxter International's Financial Health
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Baxter International displayed positive results in 3M. As of 31 December, 2025, the company achieved a solid revenue growth rate of approximately 8.03%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Baxter International's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -37.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Baxter International's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -16.87%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Baxter International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.49%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Baxter International's debt-to-equity ratio stands notably higher than the industry average, reaching 1.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.